Tag: Clinical Trials
UNC clinical trials play crucial role in FDA approval for diabetes ...
Led by John Buse, MD, PhD, director of the UNC Diabetes Care Center, the clinical research of UNC doctors and the participation of thousands of patients culminates in a new, effective, and safe daily injectable drug to combat type-2 diabetes.
UNC hearing loss experts lead clinical trials of FDA-approved heari...
Ninety-seven percent of trial participants reported hearing improvements in the first year with the use of the SYNCHRONY EAS (Electric Acoustic Stimulation) Hearing Implant System. UNC implanted more patients than any other participating hearing center.
Diabetes drug lowers risk of cardiovascular complications, kidney d...
For the first time, a large clinical trial showed across-the-board cardiovascular benefit of a diabetes drug – liraglutide – a much-needed outcome for people with type 2 diabetes.
Adding stress management to cardiac rehab cuts new heart incidents ...
UNC’s Alan Hinderliter, MD, teamed up with Duke doctors to quantify the benefit of stress management to heart health.
UNC enrolling patients in Momentum 3 Clinical Trial
UNC is one of 60 medical centers nationwide chosen to participate in the MOMENTUM 3 Clinical Trial to evaluate the effectiveness and safety of the Thoratec® HeartMate 3™ Left Ventricular Assist Device (LVAD). This multi-center study will compare the HeartMate 3 LVAD to the HeartMate II® LVAD in advanced stage heart failure patients.
Researchers from UNC Lineberger, Norway launch cancer genetics coll...
Researchers from Norway visited the cancer center last week to learn firsthand about UNCseq, a clinical trial launched in 2011 at the N.C. Cancer Hospital. In the trial, researchers use a profile of the genetic and molecular alterations in patients' tumors to try to identify targeted treatments for them.
UNC Diabetes Care Center begins recruitment for long-term study of ...
Beginning recruitment in June, the project is called the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study. UNC will enroll patients at locations in Durham and Greensboro, N.C.
Rifaximin provides significant relief of irritable bowel syndrome s...
Two studies, conducted in part at the UNC School of Medicine, found that the benefits of treatment with rifaximin persisted for 10 weeks after patients stopped taking the broad-spectrum antibiotic.